Header Logo

Connection

Christopher Goetz to Parkinson Disease

Back to Details
This is a "connection" page, showing publications Christopher Goetz has written about Parkinson Disease.
Christopher Goetz
Connection Strength
21.850
Parkinson Disease
  1. Reply to: Comment on "Summing MDS-UPDRS Parts 1?+?2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice". Mov Disord. 2023 08; 38(8):1564.
    View in: PubMed
    Score: 0.503
  2. It Is as It Was: MDS-UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum. Mov Disord. 2023 02; 38(2):342-347.
    View in: PubMed
    Score: 0.481
  3. The plight of loneliness in Parkinson's disease: New opportunities. Parkinsonism Relat Disord. 2022 Dec; 105:145-148.
    View in: PubMed
    Score: 0.477
  4. Reply to: Cognitive Effects of Deep Brain Stimulation in GBA-Related Parkinson's Disease. Ann Neurol. 2022 08; 92(2):345-346.
    View in: PubMed
    Score: 0.466
  5. Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. Ann Neurol. 2022 03; 91(3):424-435.
    View in: PubMed
    Score: 0.453
  6. Apathy in Parkinson disease: Why we should care. Neurology. 2020 11 17; 95(20):893-894.
    View in: PubMed
    Score: 0.413
  7. The Evolution-Driven Signature of Parkinson's Disease. Trends Neurosci. 2020 07; 43(7):475-492.
    View in: PubMed
    Score: 0.404
  8. Parkinson's disease: Is it a consequence of human brain evolution? Mov Disord. 2019 04; 34(4):453-459.
    View in: PubMed
    Score: 0.369
  9. What influences placebo and nocebo responses in Parkinson's disease? Mov Disord. 2018 08; 33(8):1204-1212.
    View in: PubMed
    Score: 0.357
  10. Closing the celebration of 200 years of Parkinson's Essay on the Shaking Palsy: Where do we go in the next 200 years? Mov Disord. 2017 12; 32(12):1651-1652.
    View in: PubMed
    Score: 0.338
  11. Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale. Mov Disord. 2016 12; 31(12):1865-1873.
    View in: PubMed
    Score: 0.315
  12. Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease. Mov Disord. 2016 Jan; 31(1):11-22.
    View in: PubMed
    Score: 0.296
  13. Preface. Mov Disord. 2015 Sep 15; 30(11):1441.
    View in: PubMed
    Score: 0.290
  14. Handling missing values in the MDS-UPDRS. Mov Disord. 2015 Oct; 30(12):1632-8.
    View in: PubMed
    Score: 0.279
  15. Initial management of Parkinson's disease. BMJ. 2014 Dec 19; 349:g6258.
    View in: PubMed
    Score: 0.277
  16. Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. Parkinsonism Relat Disord. 2014 Nov; 20(11):1135-9.
    View in: PubMed
    Score: 0.270
  17. Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. Mov Disord. 2014 Sep; 29(10):1252-7.
    View in: PubMed
    Score: 0.265
  18. Are patients with Parkinson's disease blind to blindsight? Brain. 2014 Jun; 137(Pt 6):1838-49.
    View in: PubMed
    Score: 0.264
  19. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain. 2014 Mar; 137(Pt 3):849-59.
    View in: PubMed
    Score: 0.260
  20. I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging. Mov Disord. 2014 Jan; 29(1):115-7.
    View in: PubMed
    Score: 0.250
  21. The Parkinson's disease multidisciplinary package. Mov Disord. 2013 May; 28(5):565.
    View in: PubMed
    Score: 0.245
  22. Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. Mov Disord. 2012 Sep 01; 27(10):1239-42.
    View in: PubMed
    Score: 0.235
  23. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol. 2013 Jan; 260(1):228-36.
    View in: PubMed
    Score: 0.235
  24. Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord. 2012 Aug; 27(9):1129-36.
    View in: PubMed
    Score: 0.233
  25. Tai chi for patients with Parkinson's disease. N Engl J Med. 2012 05 03; 366(18):1737-8; author reply 1738.
    View in: PubMed
    Score: 0.231
  26. Vibration therapy for Parkinson's disease: Charcot's studies revisited. J Parkinsons Dis. 2012; 2(1):23-7.
    View in: PubMed
    Score: 0.225
  27. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia. Mov Disord. 2012 Feb; 27(2):248-53.
    View in: PubMed
    Score: 0.224
  28. Temporal stability of the Unified Dyskinesia Rating Scale. Mov Disord. 2011 Dec; 26(14):2556-9.
    View in: PubMed
    Score: 0.221
  29. The history of Parkinson's disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2011 Sep; 1(1):a008862.
    View in: PubMed
    Score: 0.220
  30. Wearing-off scales in Parkinson's disease: critique and recommendations. Mov Disord. 2011 Oct; 26(12):2169-75.
    View in: PubMed
    Score: 0.218
  31. Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years. Mov Disord. 2011 Oct; 26(12):2196-200.
    View in: PubMed
    Score: 0.218
  32. An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother. 2011 Sep; 12(13):2009-24.
    View in: PubMed
    Score: 0.216
  33. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov Disord. 2011 Aug 01; 26(9):1781-2.
    View in: PubMed
    Score: 0.214
  34. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology. 2010 Nov 16; 75(20):1773-9.
    View in: PubMed
    Score: 0.207
  35. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010 Sep 15; 25(12):1801-8.
    View in: PubMed
    Score: 0.206
  36. Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS). Mov Disord. 2010 Jul 15; 25(9):1190-4.
    View in: PubMed
    Score: 0.203
  37. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease. Mov Disord. 2010; 25 Suppl 1:S104-9.
    View in: PubMed
    Score: 0.196
  38. Hallucinations in Parkinson disease. Nat Rev Neurol. 2009 Jun; 5(6):331-42.
    View in: PubMed
    Score: 0.188
  39. Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Mov Disord. 2009 Apr 15; 24(5):635-46.
    View in: PubMed
    Score: 0.187
  40. Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol. 2008 Dec; 64 Suppl 2:S81-92.
    View in: PubMed
    Score: 0.182
  41. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.181
  42. Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2008 Oct 30; 23(14):2004-14.
    View in: PubMed
    Score: 0.181
  43. Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2008 Oct 30; 23(14):2015-25.
    View in: PubMed
    Score: 0.181
  44. The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies. Neurology. 2008 Aug 26; 71(9):677-84.
    View in: PubMed
    Score: 0.179
  45. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Mov Disord. 2008 Aug 15; 23(11):1541-5.
    View in: PubMed
    Score: 0.178
  46. Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments. Mov Disord. 2008 Jul 30; 23(10):1479-82.
    View in: PubMed
    Score: 0.178
  47. Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies. Int J Geriatr Psychiatry. 2008 Jun; 23(6):598-603.
    View in: PubMed
    Score: 0.176
  48. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord. 2008 Apr 15; 23(5):700-7.
    View in: PubMed
    Score: 0.174
  49. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008 Apr 15; 23(5):690-9.
    View in: PubMed
    Score: 0.174
  50. Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord. 2008 Mar 15; 23(4):484-500.
    View in: PubMed
    Score: 0.173
  51. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord. 2007 Jun 15; 22(8):1061-8.
    View in: PubMed
    Score: 0.164
  52. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2007 Jun 15; 22(8):1077-92.
    View in: PubMed
    Score: 0.164
  53. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord. 2007 Jan 15; 22(2):179-86.
    View in: PubMed
    Score: 0.160
  54. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
    View in: PubMed
    Score: 0.159
  55. Does seasonal variation affect hallucinations in PD? A longitudinal study. Mov Disord. 2006 Jun; 21(6):863-5.
    View in: PubMed
    Score: 0.153
  56. The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol. 2006 May; 63(5):713-6.
    View in: PubMed
    Score: 0.152
  57. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006 Feb; 21(2):267-70.
    View in: PubMed
    Score: 0.149
  58. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 2005 May; 20(5):523-39.
    View in: PubMed
    Score: 0.142
  59. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005 Jan 11; 64(1):81-6.
    View in: PubMed
    Score: 0.139
  60. Movement disorders: understanding clinical trials. Lancet Neurol. 2005 Jan; 4(1):5-6.
    View in: PubMed
    Score: 0.139
  61. Assuring interrater reliability for the UPDRS motor section: utility of the UPDRS teaching tape. Mov Disord. 2004 Dec; 19(12):1453-6.
    View in: PubMed
    Score: 0.138
  62. Short-term and practice effects of metronome pacing in Parkinson's disease patients with gait freezing while in the 'on' state: randomized single blind evaluation. Parkinsonism Relat Disord. 2004 Dec; 10(8):507-10.
    View in: PubMed
    Score: 0.138
  63. Wheeled and standard walkers in Parkinson's disease patients with gait freezing. Parkinsonism Relat Disord. 2003 Oct; 10(1):9-14.
    View in: PubMed
    Score: 0.127
  64. Impact of placebo assignment in clinical trials of Parkinson's disease. Mov Disord. 2003 Oct; 18(10):1146-9.
    View in: PubMed
    Score: 0.127
  65. Coping strategies for visual hallucinations in Parkinson's disease. Mov Disord. 2003 Jul; 18(7):831-2.
    View in: PubMed
    Score: 0.125
  66. Summing MDS-UPDRS Parts 1?+?2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice. Mov Disord. 2023 07; 38(7):1363-1364.
    View in: PubMed
    Score: 0.123
  67. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003 Apr; 60(4):529-33.
    View in: PubMed
    Score: 0.123
  68. An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson's disease participants. Nat Commun. 2023 02 18; 14(1):926.
    View in: PubMed
    Score: 0.122
  69. Cross-Cultural Differences in Patient Perceptions of Dyskinesia in Parkinson's Disease. Mov Disord. 2023 04; 38(4):688-692.
    View in: PubMed
    Score: 0.121
  70. Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings. Mov Disord. 2023 03; 38(3):453-463.
    View in: PubMed
    Score: 0.121
  71. Treatment of advanced Parkinson's disease: an evidence-based analysis. Adv Neurol. 2003; 91:213-28.
    View in: PubMed
    Score: 0.121
  72. Jean-Martin Charcot and the aging brain. Arch Neurol. 2002 Nov; 59(11):1821-4.
    View in: PubMed
    Score: 0.119
  73. Intestinal microbiota and neuroinflammation in Parkinson's disease: At the helm of the gut-brain axis. Int Rev Neurobiol. 2022; 167:81-99.
    View in: PubMed
    Score: 0.118
  74. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol. 2002 Aug; 59(8):1249-52.
    View in: PubMed
    Score: 0.117
  75. Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine. Mov Disord. 2022 08; 37(8):1749-1755.
    View in: PubMed
    Score: 0.116
  76. Gut microbial metabolites in Parkinson's disease: Association with lifestyle, disease characteristics, and treatment status. Neurobiol Dis. 2022 08; 170:105780.
    View in: PubMed
    Score: 0.116
  77. Gut-Brain Communication in Parkinson's Disease: Enteroendocrine Regulation by GLP-1. Curr Neurol Neurosci Rep. 2022 07; 22(7):335-342.
    View in: PubMed
    Score: 0.116
  78. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord. 2002 Mar; 17(2):283-8.
    View in: PubMed
    Score: 0.114
  79. Rating scales for medication adherence in people living with Parkinson's disease: a systematic review protocol. JBI Evid Synth. 2022 01 01; 20(1):260-269.
    View in: PubMed
    Score: 0.113
  80. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA. 2021 09 14; 326(10):926-939.
    View in: PubMed
    Score: 0.110
  81. Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change. Mov Disord. 2021 12; 36(12):2853-2861.
    View in: PubMed
    Score: 0.109
  82. Validation of the Polish version of the Unified Dyskinesia Rating Scale (UDysRS). Neurol Neurochir Pol. 2021; 55(2):186-194.
    View in: PubMed
    Score: 0.106
  83. In Support of Electronic Versions of Movement Disorder Society Rating Scales. Mov Disord. 2021 01; 36(1):270-271.
    View in: PubMed
    Score: 0.105
  84. COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel? J Parkinsons Dis. 2021; 11(1):3-8.
    View in: PubMed
    Score: 0.105
  85. Validation of the Hebrew Version of the Unified Dyskinesia Rating Scale. Neuroepidemiology. 2020; 54(4):356-362.
    View in: PubMed
    Score: 0.101
  86. Item Response Theory Analysis of the MDS-UPDRS Motor Examination: Tremor vs. Nontremor Items. Mov Disord. 2020 09; 35(9):1587-1595.
    View in: PubMed
    Score: 0.101
  87. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. 2019 10 01; 93(14):e1328-e1338.
    View in: PubMed
    Score: 0.096
  88. Successful use of the Unified Dyskinesia Rating Scale regardless of PD- or dyskinesia-duration. Parkinsonism Relat Disord. 2019 10; 67:113-116.
    View in: PubMed
    Score: 0.096
  89. Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. Mov Disord. 2019 06; 34(6):791-798.
    View in: PubMed
    Score: 0.094
  90. Validation of the MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2018 10; 33(10):1601-1608.
    View in: PubMed
    Score: 0.089
  91. Movement disorder society criteria for clinically established early Parkinson's disease. Mov Disord. 2018 10; 33(10):1643-1646.
    View in: PubMed
    Score: 0.089
  92. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. Parkinsonism Relat Disord. 2018 07; 52:83-89.
    View in: PubMed
    Score: 0.087
  93. Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. Mov Disord. 2018 03; 33(3):499-500.
    View in: PubMed
    Score: 0.086
  94. Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. Mov Disord. 2018 02; 33(2):208-218.
    View in: PubMed
    Score: 0.085
  95. Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2017 Dec; 45:7-12.
    View in: PubMed
    Score: 0.084
  96. Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. Mov Disord. 2017 09; 32(9):1335-1336.
    View in: PubMed
    Score: 0.082
  97. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann Neurol. 2017 Jan; 81(1):46-57.
    View in: PubMed
    Score: 0.080
  98. Disability Rating Scales in Parkinson's Disease: Critique and Recommendations. Mov Disord. 2016 10; 31(10):1455-1465.
    View in: PubMed
    Score: 0.078
  99. Abolishing the 1-year rule: How much evidence will be enough? Mov Disord. 2016 11; 31(11):1623-1627.
    View in: PubMed
    Score: 0.078
  100. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Mov Disord. 2016 09; 31(9):1373-80.
    View in: PubMed
    Score: 0.076
  101. The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurol. 2016 05; 15(6):546-8.
    View in: PubMed
    Score: 0.076
  102. Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations. Mov Disord. 2016 09; 31(9):1342-55.
    View in: PubMed
    Score: 0.075
  103. Parkinson's disease-related fatigue: A case definition and recommendations for clinical research. Mov Disord. 2016 05; 31(5):625-31.
    View in: PubMed
    Score: 0.075
  104. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.
    View in: PubMed
    Score: 0.071
  105. Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests? Mov Disord. 2015 Mar; 30(3):402-6.
    View in: PubMed
    Score: 0.069
  106. The past, present, and future of telemedicine for Parkinson's disease. Mov Disord. 2014 Jun; 29(7):871-83.
    View in: PubMed
    Score: 0.066
  107. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord. 2014 Apr; 29(4):454-62.
    View in: PubMed
    Score: 0.066
  108. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb; 71(2):141-50.
    View in: PubMed
    Score: 0.065
  109. Using cognitive pretesting in scale development for Parkinson's disease: the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) example. J Parkinsons Dis. 2014; 4(3):395-404.
    View in: PubMed
    Score: 0.065
  110. Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. Mov Disord. 2013 Dec; 28(14):1972-9.
    View in: PubMed
    Score: 0.064
  111. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Mov Disord. 2013 Dec; 28(14):1980-6.
    View in: PubMed
    Score: 0.064
  112. Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. Mov Disord. 2014 Feb; 29(2):169-76.
    View in: PubMed
    Score: 0.063
  113. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. Parkinsonism Relat Disord. 2013 Oct; 19(10):889-93.
    View in: PubMed
    Score: 0.062
  114. Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. Parkinsonism Relat Disord. 2013 Sep; 19(9):806-11.
    View in: PubMed
    Score: 0.062
  115. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord. 2013 Nov; 28(13):1816-22.
    View in: PubMed
    Score: 0.062
  116. Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy. PLoS One. 2013; 8(3):e58403.
    View in: PubMed
    Score: 0.061
  117. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord. 2013 May; 28(5):668-70.
    View in: PubMed
    Score: 0.061
  118. Which dyskinesia scale best detects treatment response? Mov Disord. 2013 Mar; 28(3):341-6.
    View in: PubMed
    Score: 0.061
  119. Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. Mov Disord. 2012 May; 27(6):727-34.
    View in: PubMed
    Score: 0.057
  120. Subject-investigator reproducibility of the Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2012 Mar; 18(3):230-3.
    View in: PubMed
    Score: 0.056
  121. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2011 Oct; 26 Suppl 3:S2-41.
    View in: PubMed
    Score: 0.055
  122. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011 Oct; 26 Suppl 3:S42-80.
    View in: PubMed
    Score: 0.055
  123. Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease. Mov Disord. 2012 Jan; 27(1):79-83.
    View in: PubMed
    Score: 0.055
  124. Health-related quality-of-life scales in Parkinson's disease: critique and recommendations. Mov Disord. 2011 Nov; 26(13):2371-80.
    View in: PubMed
    Score: 0.054
  125. The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. Mov Disord. 2011 Sep; 26(11):1985-92.
    View in: PubMed
    Score: 0.054
  126. Priorities in Parkinson's disease research. Nat Rev Drug Discov. 2011 May; 10(5):377-93.
    View in: PubMed
    Score: 0.054
  127. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010 Aug; 67(8):996-1001.
    View in: PubMed
    Score: 0.051
  128. Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov Disord. 2010 Jul 15; 25(9):1131-42.
    View in: PubMed
    Score: 0.051
  129. Shaking up the Salpetriere: Jean-Martin Charcot and mercury-induced tremor. Neurology. 2010 May 25; 74(21):1739-42.
    View in: PubMed
    Score: 0.050
  130. Missing pieces in the Parkinson's disease puzzle. Nat Med. 2010 Jun; 16(6):653-61.
    View in: PubMed
    Score: 0.050
  131. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord. 2010 May 15; 25(7):805-22.
    View in: PubMed
    Score: 0.050
  132. Scales to evaluate psychosis in Parkinson's disease. Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S38-41.
    View in: PubMed
    Score: 0.049
  133. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord. 2009 Oct 30; 24(14):2081-90.
    View in: PubMed
    Score: 0.048
  134. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol. 2009 Jul-Aug; 32(4):189-92.
    View in: PubMed
    Score: 0.047
  135. Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device. Mov Disord. 2009 Mar 15; 24(4):551-6.
    View in: PubMed
    Score: 0.046
  136. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord. 2009 Feb 15; 24(3):336-43.
    View in: PubMed
    Score: 0.046
  137. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord. 2008 Dec 15; 23(16):2398-403.
    View in: PubMed
    Score: 0.046
  138. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008 Jun; 65(6):716-23.
    View in: PubMed
    Score: 0.044
  139. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007 Dec; 22(16):2314-24.
    View in: PubMed
    Score: 0.042
  140. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007 Sep 15; 22(12):1689-707; quiz 1837.
    View in: PubMed
    Score: 0.042
  141. Levodopa-induced dyskinesias. Mov Disord. 2007 Jul 30; 22(10):1379-1389.
    View in: PubMed
    Score: 0.041
  142. The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol. 2007 May; 66(5):329-36.
    View in: PubMed
    Score: 0.041
  143. The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol. 2007 Apr; 66(4):251-7.
    View in: PubMed
    Score: 0.041
  144. Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol. 2007 Feb; 64(2):261-5.
    View in: PubMed
    Score: 0.040
  145. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006 Dec; 21(12):2078-81.
    View in: PubMed
    Score: 0.040
  146. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb; 63(2):210-6.
    View in: PubMed
    Score: 0.037
  147. Hallucinations in Parkinson disease in the prelevodopa era. Neurology. 2006 Jan 10; 66(1):93-8.
    View in: PubMed
    Score: 0.037
  148. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord. 2005 Feb; 20(2):130-40.
    View in: PubMed
    Score: 0.035
  149. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb; 57(2):197-203.
    View in: PubMed
    Score: 0.035
  150. Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18.
    View in: PubMed
    Score: 0.035
  151. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004 Aug; 61(8):1280-4.
    View in: PubMed
    Score: 0.034
  152. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003 Dec 15; 12(24):3259-67.
    View in: PubMed
    Score: 0.032
  153. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003 Sep; 54(3):403-14.
    View in: PubMed
    Score: 0.032
  154. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol. 2003 Jul; 60(7):975-80.
    View in: PubMed
    Score: 0.031
  155. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol. 2003 May; 53(5):624-9.
    View in: PubMed
    Score: 0.031
  156. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet. 2003 Apr; 72(4):804-11.
    View in: PubMed
    Score: 0.031
  157. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet. 2002 May 04; 359(9317):1589-98.
    View in: PubMed
    Score: 0.029
  158. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002 Apr; 70(4):985-93.
    View in: PubMed
    Score: 0.028
  159. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct; 30(12):1591-601.
    View in: PubMed
    Score: 0.018
  160. MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2015 Oct; 30(12):1600-11.
    View in: PubMed
    Score: 0.018
  161. A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study. Mov Disord. 2014 May; 29(6):743-9.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.